Imperial College London
Portrait Picture

ProfessorAzraGhani

Faculty of Medicine, School of Public Health

Chair in Infectious Disease Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 5764a.ghani Website

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Slater:2020:10.1016/S1473-3099(19)30633-4,
author = {Slater, HC and Foy, BD and Kobylinski, K and Chaccour, C and Watson, OJ and Hellewell, J and Aljayyoussi, G and Bousema, T and Burrows, J and D'Alessandro, U and Alout, H and Ter, Kuile FO and Walker, PGT and Ghani, AC and Smit, MR},
doi = {10.1016/S1473-3099(19)30633-4},
journal = {Lancet Infectious Diseases},
pages = {498--508},
title = {Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study},
url = {http://dx.doi.org/10.1016/S1473-3099(19)30633-4},
volume = {20},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Ivermectin is a potential new vector control tool to reduce malaria transmission. Mosquitoes feeding on a bloodmeal containing ivermectin have a reduced lifespan, meaning they are less likely to live long enough to complete sporogony and become infectious. We aimed to estimate the effect of ivermectin on malaria transmission in various scenarios of use. METHODS: We validated an existing population-level mathematical model of the effect of ivermectin mass drug administration (MDA) on the mosquito population and malaria transmission against two datasets: clinical data from a cluster- randomised trial done in Burkina Faso in 2015 wherein ivermectin was given to individuals taller than 90 cm and entomological data from a study of mosquito outcomes after ivermectin MDA for onchocerciasis or lymphatic filariasis in Burkina Faso, Senegal, and Liberia between 2008 and 2013. We extended the existing model to include a range of complementary malaria interventions (seasonal malaria chemoprevention and MDA with dihydroartemisinin-piperaquine) and to incorporate new data on higher doses of ivermectin with a longer mosquitocidal effect. We consider two ivermectin regimens: a single dose of 400 μg/kg (1×400 μg/kg) and three consecutive daily doses of 300 μg/kg per day (3×300 μg/kg). We simulated the effect of these two doses in a range of usage scenarios in different transmission settings (highly seasonal, seasonal, and perennial). We report percentage reductions in clinical incidence and slide prevalence. FINDINGS: We estimate that MDA with ivermectin will reduce prevalence and incidence and is most effective in areas with highly seasonal transmission. In a highly seasonal moderate transmission setting, three rounds of ivermectin only MDA at 3×300 μg/kg (rounds spaced 1 month apart) and 70% coverage is predicted to reduce clinical incidence by 71% and prevalence by 34%. We predict that adding ivermectin MDA to seasonal malaria ch
AU  - Slater,HC
AU  - Foy,BD
AU  - Kobylinski,K
AU  - Chaccour,C
AU  - Watson,OJ
AU  - Hellewell,J
AU  - Aljayyoussi,G
AU  - Bousema,T
AU  - Burrows,J
AU  - D'Alessandro,U
AU  - Alout,H
AU  - Ter,Kuile FO
AU  - Walker,PGT
AU  - Ghani,AC
AU  - Smit,MR
DO  - 10.1016/S1473-3099(19)30633-4
EP  - 508
PY  - 2020///
SN  - 1473-3099
SP  - 498
TI  - Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study
T2  - Lancet Infectious Diseases
UR  - http://dx.doi.org/10.1016/S1473-3099(19)30633-4
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31948767
UR  - https://www.sciencedirect.com/science/article/pii/S1473309919306334?via%3Dihub
UR  - http://hdl.handle.net/10044/1/76363
VL  - 20
ER  -
Download